Sab Biotherapeutics Stock Price on December 18, 2024
| SABS Stock | USD 4.10 0.18 4.21% |
If you're considering investing in SAB Stock, it is important to understand the factors that can impact its price. As of today, the current price of SAB Biotherapeutics stands at 4.10, as last reported on the 27th of December, with the highest price reaching 4.32 and the lowest price hitting 4.00 during the day. SAB Biotherapeutics is dangerous given 3 months investment horizon. SAB Biotherapeutics retains Efficiency (Sharpe Ratio) of 0.11, which indicates the company had a 0.11% return per unit of risk over the last 3 months. We have analyzed twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.14% are justified by taking the suggested risk. Use SAB Biotherapeutics Semi Deviation of 6.67, standard deviation of 9.97, and Market Risk Adjusted Performance of 1.33 to evaluate company specific risk that cannot be diversified away.
At this time, SAB Biotherapeutics' Common Stock Shares Outstanding is comparatively stable compared to the past year. Sale Purchase Of Stock is expected to grow at the current pace this year, whereas Liabilities And Stockholders Equity is likely to drop slightly above 63.5 M in 2024. . At this time, SAB Biotherapeutics' Price Book Value Ratio is comparatively stable compared to the past year. Price To Book Ratio is likely to gain to 0.70 in 2024, whereas Price Earnings Ratio is likely to drop (0.95) in 2024. SAB Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
SAB |
Sharpe Ratio = 0.1114
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SABS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.2 actual daily | 90 90% of assets are less volatile |
Expected Return
| 1.14 actual daily | 22 78% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average SAB Biotherapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SAB Biotherapeutics by adding it to a well-diversified portfolio.
Price Book 1.0254 | Enterprise Value Ebitda (1.49) | Price Sales 25.5026 | Shares Float 6 M | Wall Street Target Price 12.4 |
Related Headline
Cadrenal Therapeutics, Headline on 18th of December 2024
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morg... by finance.yahoo.com
PONTE VEDRA, Fla., December 18, 2024--Cadrenal Therapeutics, Inc. , announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025 in San Francisco, California. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist in advanced clinical development and designed to be a superior and safer chronic anticoagulant
SAB Biotherapeutics Valuation on December 18, 2024
It is possible to determine the worth of SAB Biotherapeutics on a given historical date. On December 18, 2024 SAB was worth 4.05 at the beginning of the trading date compared to the closed value of 3.34. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of SAB Biotherapeutics stock. Still, in general, we apply an absolute valuation method to find SAB Biotherapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of SAB Biotherapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against SAB Biotherapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 3.87 | 4.15 | 3.80 | 4.03 | 41,151 | |
12/18/2024 | 4.05 | 4.19 | 3.32 | 3.34 | 117,830 |
| 3.45 | 4.50 | 3.45 | 3.90 | 209,920 |
| Backtest SAB Biotherapeutics | | | SAB Biotherapeutics History | | | SAB Biotherapeutics Valuation | Previous | Next |
SAB Biotherapeutics Trading Date Momentum on December 18, 2024
| On December 19 2024 SAB Biotherapeutics was traded for 3.90 at the closing time. The top price for the day was 4.50 and the lowest listed price was 3.45 . The trading volume for the day was 209.9 K. The trading history from December 19, 2024 was a factor to the next trading day price appreciation. The trading price change against the next closing price was 16.77% . The trading price change against the current closing price is 26.35% . |
SAB Biotherapeutics Fundamentals Correlations and Trends
By evaluating SAB Biotherapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. SAB financial account trend analysis is a perfect complement when working with valuation or volatility modules.About SAB Biotherapeutics Stock history
SAB Biotherapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for SAB is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in SAB Biotherapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing SAB Biotherapeutics stock prices may prove useful in developing a viable investing in SAB Biotherapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 5.5 M | 9.4 M | |
| Net Loss | -16.9 M | -16 M |
SAB Biotherapeutics Stock Technical Analysis
SAB Biotherapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
SAB Biotherapeutics Period Price Range
Low | December 27, 2024
| High |
0.00 | 0.00 |
SAB Biotherapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
SAB Biotherapeutics December 27, 2024 Market Strength
Market strength indicators help investors to evaluate how SAB Biotherapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading SAB Biotherapeutics shares will generate the highest return on investment. By undertsting and applying SAB Biotherapeutics stock market strength indicators, traders can identify SAB Biotherapeutics entry and exit signals to maximize returns
SAB Biotherapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for SAB Biotherapeutics' price direction in advance. Along with the technical and fundamental analysis of SAB Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of SAB to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0821 | |||
| Jensen Alpha | 0.8757 | |||
| Total Risk Alpha | 0.3619 | |||
| Sortino Ratio | 0.1224 | |||
| Treynor Ratio | 1.32 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.